EPI-8207

EPI-8207 is a next-generation bifunctional small molecule degrader developed by ESSA Pharma, utilizing their proprietary ANITAC (AR NTD-Inhibiting Proteolysis-Targeting Chimera) platform. It is designed to target the N-terminal domain (NTD) of the androgen receptor (AR), a region essential for the receptor's transcriptional activity. Unlike conventional AR-targeted therapies that bind to the C-terminal ligand-binding domain (LBD) and are susceptible to resistance via LBD mutations or splice variants (e.g., AR-V7), EPI-8207 induces the degradation of both full-length AR and its truncated splice variants. This mechanism of action is intended to provide a more comprehensive blockade of androgen signaling, specifically for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have developed resistance to current standard-of-care anti-androgens.